Successful Treatment of Trigeminal Neuralgia With Milnacipran
Authors:
- Keizo YoshidaKYKeizo Yoshida
- Hiroyuki KimuraHKHiroyuki Kimura
- Norio OzakiNONorio Ozaki
- Kenichi KuritaKKKenichi Kurita
- 1 May 2007
- journal article
- case report
- Published by Wolters Kluwer Health in Clinical Neuropharmacology
- Vol. 30 (3) , 183-185
Abstract
Paroxysmal pain in a 64-year-old woman diagnosed with trigeminal neuralgia disappeared with the administration of carbamazepine, but carbamazepine had to be discontinued because of intolerable lassitude and liver dysfunction. Afterward, the paroxysmal pain reoccurred, and depressive symptoms appeared. Milnacipran was then administered at a dosage of 50 mg/d for 2 months, and the paroxysmal pain and depression disappeared completely. Carbamazepine is the drug of first choice for trigeminal neuralgia, but the present results suggest that milnacipran is worth investigating for patients who do not respond to carbamazepine, who cannot stay on carbamazepine because of side effects, and who exhibit depressive symptoms.Keywords
This publication has 5 references indexed in Scilit:
- Eye-wiping test: A sensitive animal model for acute trigeminal pain studiesBrain Research Protocols, 2005
- Opioid and monoamine systems mediate the discriminative stimulus of tramadol in ratsEuropean Journal of Pharmacology, 2004
- Trigeminal neuralgia: Pathology and pathogenesisBrain, 2001
- The Long-Term Outcome of Microvascular Decompression for Trigeminal NeuralgiaNew England Journal of Medicine, 1996
- A pharmacological study of the modulation of neuronal and behavioural nociceptive responses in the rat trigeminal regionBrain Research, 1995